TABLE 1.

Screened drugs with potential for prophylaxis studies, and their correspondent number of citations and mechanism of action.

	Drug	Citations	Mechanism of action
1	Aciclovir	World Health Organization (2020)	Nucleoside analog
2	Amantadine	World Health Organization (2020)	Interferes with transmembrane M2 protein
3	Amprenavir	World Health Organization (2020)	Protease inhibitor (HIV)
4	Baloxavir marboxil	Xie et al. (2020)	Endonuclease inhibitor—inhibits the initiation of mRNA synthesis
5	Darunavir	Zhang et al. (2020)	Second generation protease inhibitor
6	Entecavir	World Health Organization (2020)	Guanine analogue (HCV)
7	Faldaprevir	World Health Organization (2020)	HCV protease inhibitor
8	Faviparivir	Beigel et al. (2019)	Prodrug of a purine nucleotide, favipiravir ribofuranosyl-5′-triphosphate—RNA polymerase inhibitor
9	Galidesivir	Mayer et al. (2015)	Protease inhibitor—Adenine analog
10	GS-441524	Xie et al. (2020)	Adenisin nucleoside analog
11	Indinavir	World Health Organization (2020)	HIV protease specific inhibitor
12	Lopinavir	Beigel et al. (2019)	Aspartic acid protease (HIV) inhibitor
13	Nelfinavir	Vellingiri et al. (2020)	Protease inhibitor
14	Oseltamivir	Vellingiri et al. (2020)	Active neuraminidase inhibitor
15	Pleconaril	Xie et al. (2020)	Viral capsid inhibitor
16	Remdesivir	Cheng (2019)	Prodrug—active nucleoside analog C-adenosine triphosphate—(Ebola)
17	Ribavirin	Kang et al. (2020)	Nucleoside analogue (guanine)—inhibits viral RNA-dependent RNA polymerase
18	Sofosbuvir	Glushkov et al. (1999)	Nucleoside analog—hepatitis C virus NS5B polymerase inhibitor
19	Tenofovir	Glushkov et al. (1999)	Acyclic nucleoside analog adenosine monophosphate
20	Tipranavir	Xie et al. (2020)	HIV protease enzyme inhibitor
21	Umifenovir	Zhou et al. (2020)	Hemagglutinin inhibitor (influenza)
22	Zanamivir	World Health Organization (2020)	Neuraminidase inhibitor